Status:
TERMINATED
PET CT With HX4 in Cervix Cancer
Lead Sponsor:
Maastricht Radiation Oncology
Conditions:
Cervix Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study is: 1. to determine if tumor hypoxia can be accurately visualised with \[18F\]HX4 PET imaging in cervix cancer, 2. to correlate the \[18F\]HX4 PET images with blood and tissue m...
Detailed Description
Tumor hypoxia is the situation where tumor cells are or have been deprived of oxygen. Hypoxic tumor cells are usually more resistant to radiotherapy and chemotherapy and more likely to develop metasta...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Histologically confirmed cervix carcinoma (squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma)
- tumor stages FIGO IB - IVA
- WHO performance status 0 to 2
- Scheduled for primary curative radiotherapy (either or not combined with chemotherapy or hyperthermia)
- No previous surgery to the Cervix
- No previous radiation to the Cervix
- The patient is willing and capable to comply with study procedures
- 18 years or older
- Written informed consent before patient registration
- Exclusion criteria
- Recent (\< 3 months) myocardial infarction
- Uncontrolled infectious disease
- Pregnant or breast feeding and/or not willing to take adequate contraceptive measures during the study
Exclusion
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT02233387
Start Date
November 1 2014
End Date
May 1 2018
Last Update
March 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MAASTRO clinic
Maastricht, Netherlands, 6229 ET